RxDoctor Payments Data

Nicole Vasher

Psychiatric/Mental Health · Lansing, MINPI 1508468257

Payments from drug & device makers

$1,024in general payments, 2019–2025

Across 59 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$690
  • Neurocrine Biosciences, Inc.$122
  • Ironshore Pharmaceuticals Inc.$46
  • AbbVie$42
  • Otsuka America Pharmaceutical, Inc.$39
  • Idorsia Pharmaceuticals US Inc$21
  • plus $64 from 4 others

What the payments were for

  • Food & beverage$96594%
  • Education$596%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,024 in reported general payments places this provider in the 60th percentile of 638 psychiatric/mental health providers in Michigan.

See all psychiatric/mental health providers in Michigan

Medicare billing

Part B allowed, 2024
$47,529
Medicare patients
47
Services billed
539

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate21$168,954
Invega SustennaPaliperidone Palmitate23$74,371
VraylarCariprazine Hcl25$35,824
CaplytaLumateperone Tosylate19$31,043
AuvelityDextromethorphan Hbr/Bupropion17$17,331
TrintellixVortioxetine Hydrobromide14$8,506
VyvanseLisdexamfetamine Dimesylate22$8,384
Chlorpromazine Hcl12$7,347
Venlafaxine Hcl ErVenlafaxine Hcl96$6,607
Duloxetine Hcl59$5,781
Aripiprazole74$2,860
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine83$2,454
Desvenlafaxine Succinate ErDesvenlafaxine Succinate18$2,307
Lamotrigine99$2,176
Trazodone Hcl141$1,970

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$122$168,95421 claims
Johnson & JohnsonInvega Sustenna$17$74,37123 claims
AbbVieVraylar$42$35,82425 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$690$31,04319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 638 psychiatric/mental health providers in Michigan.

Other psychiatric/mental health in Lansing

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →